INFECTION DISEASE
Steering Committee Meeting
August 28-29, 2012

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

PUBLIC AGENDA

DAY ONE DIAL-IN INFORMATION

Dial-In Number: 1-877-303-9138
Conference ID: 98633135
Press *0 at any time for operator assistance

Audio Streaming Instructions:
On the day of the event, follow the instructions below approximately 15 minutes before the scheduled start time.
1. Direct your web browser to: http://nqf.commpartners.com (Notice there is no www.)
2. In the “Enter a Meeting” box, type this code: 625433
3. Complete the user information shown in the required fields (indicated by asteriks).
   Click "Submit."
4. Please be sure to turn up your speakers.
5. To comment at any time during the meeting, please use the dial-in number above.

Day 1: August 28, 2012

9:00am Welcome
Steven Brotman, MD, JD, Co-chair
Edward Septimus, MD, Co-chair
Reva Winkler, MD, MPH, Senior Director

9:10am Introductions and Disclosure of Interest
Ann Hammersmith, JD, General Counsel

9:25am Project Introduction and Overview of Evaluation Process
Dr. Winkler
Consideration of Candidate Measures

- 0058: Avoidance of antibiotic treatment in adults with acute bronchitis (NCQA)
- 0069: Appropriate treatment for children with upper respiratory infection (URI) (NCQA)

Break

Consideration of Candidate Measures (Continued)

- 0500: Severe sepsis and septic shock: Management bundle (Henry Ford)
- 0399: Hepatitis C: Hepatitis A vaccination (paired with 0400) (AMA-PCPI)
- 0400: Hepatitis C: Hepatitis B vaccination (paired with 0399) (AMA-PCPI)
- 0393: Hepatitis C: Testing for chronic hepatitis C-Confirmation of hepatitis C viremia (AMA-PCPI)
- 0584: Hepatitis C: Viral load test (Resolution Health)

NQF Member and Public Comment

Lunch

Consideration of Candidate Measures (Continued)

- 0395: Hepatitis C ribonucleic acid (RNA) testing before initiating treatment (paired with 0396) (AMA-PCPI)
- 0396: HCV genotype testing prior to treatment (paired with 0395) (AMA-PCPI)
- 0397: Hepatitis C: Antiviral treatment prescribed (AMA-PCPI)
- 0398: Hepatitis C: HCV RNA testing at week 12 of treatment (AMA-PCPI)
- 0394: Hepatitis C: Counseling regarding use of contraception prior to antiviral treatment (AMA-PCPI)
- 0401: Hepatitis C: Counseling regarding risk of alcohol consumption (AMA-PCPI)

Related and Competing Measures: Hepatitis C

Break

Consideration of Candidate Measures (Continued)

- 0298: Central line bundle compliance (IHI)
- 0412: HIV/AIDS: Hepatitis B vaccination (NCQA)
- 0404: HIV/AIDS: CD4 cell count or percentage performed (NCQA)
5:15pm  NQF Member and Public Comment

5:30 pm  Adjourn

---

**DAY TWO DIAL-IN INFORMATION**

Dial-In Number: 1-877-303-9138  
Conference ID: 98642582  
Press *0 at any time for operator assistance

**Audio Streaming Instructions:**
On the day of the event, follow the instructions below approximately 15 minutes before the scheduled start time.  
1. Direct your web browser to: http://nqf.commpartners.com (Notice there is no www.)  
2. In the "Enter a Meeting" box, type this code: **534557**  
3. Complete the user information shown in the required fields (indicated by asterisks). Click "Submit."  
4. Please be sure to turn up your speakers.  
5. To comment at any time during the meeting, please use the dial-in number above.

---

**Day 2: August 29, 2012**

8:30am  **Welcome, Recap of Day 1**  
  *Dr. Brotman*  
  *Dr. Septimus*

8:45am  **Consideration of Candidate Measures (Continued)**  
  - 0405: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis (NCQA)  
  - 2083: Prescription of HIV antiretroviral therapy (HRSA)  
  - 0406: HIV/AIDS: Adolescent and adult patients who are prescribed potent antiretroviral therapy (NCQA)  
  - 0407: HIV/AIDS: HIV RNA control after six months of potent antiretroviral therapy (NCQA)  
  - 2082: HIV viral load suppression (HRSA)

10:30am  **Break**

10:45am  **Consideration of Candidate Measures (Continued)**  
  - 2081: Newly enrolled in medical care (HRSA)

WWW.QUALITYFORUM.ORG
- 2079: Medical visit frequency (HRSA)
- 2080: Gap in medical visits (HRSA)
- 0403: HIV/AIDS: Medical visit (NCQA)

12:15pm  NQF Member and Public Comment

12:30pm  Lunch

1:00pm   Consideration of Candidate Measures (Continued)
- 0408: HIV/AIDS: Tuberculosis (TB) screening (NCQA)
- 0409: HIV/AIDS: Sexually transmitted diseases-Screening for chlamydia, gonorrhea, and syphilis (NCQA)

Related and Competing Measures: HIV/AIDS

3:00pm  Additional Discussion Topics
- Measure Gaps
- Disparity-sensitive measures

3:30pm  NQF Member and Public Comment

3:45pm  Next Steps/Committee Timeline
  Dr. Winkler
  Mrs. Morgan

4:00pm  Adjourn